Cardiac Devices Marked the Highest Risk in Candidozyma auris Candidemia
Metastatic spread after Candidozyma auris candidemia was not a rare complication in this Spanish tertiary-care cohort. Among 108 adults with bloodstream infection seen between 2016 and 2024, 24 developed metastatic infection, a rate of 22.2% that places this yeast in the same clinical frame as other invasive candidiasis syndromes capable of seeding distant organs after the bloodstream phase begins.
The complication pattern was familiar in one sense and unsettling in another. Endocarditis led the list at 7.4%, while osteoarticular infection, meningitis, and hepatosplenic infection each occurred in 3.7% of patients. Chorioretinitis appeared once, and three additional patients developed later complications such as aneurysm sac infection or subcutaneous abscess. No patient had more than one metastatic focus, yet the burden remained clinically important because disseminated disease carried a clear mortality penalty.
Dissemination Followed a Familiar Candida Biology, but the Device Signal Stood Out
The microbiologic and clinical logic behind dissemination is straightforward. A yeast that persists in the bloodstream can seed damaged endothelium, prosthetic material, bone, the central nervous system, and hepatosplenic tissue. In this cohort, the strongest signal clustered around intracardiac foreign material. A cardiac device or prosthetic valve was present more often in patients who developed metastatic infection than in those who did not, and multivariable Fine–Gray regression identified that variable as the only independent predictor of metastatic complications, with a subdistribution hazard ratio of 2.89 and a 95% confidence interval of 1.21 to 6.91.
The association weakened in a sensitivity analysis restricted to patients who underwent echocardiography, a reminder that diagnostic intensity can shape how often endocarditis and other cardiac complications are found. Still, the bedside implication is hard to ignore. A prosthetic valve, pacemaker, implantable cardioverter-defibrillator, or left ventricular assist device offers an anatomic surface on which a bloodstream infection can persist, shielded from host clearance and harder to sterilize with antifungal therapy alone.
Persistent candidemia also raised concern. In the day-5 landmark analysis, ongoing bloodstream positivity was linked to a higher risk of metastatic infection, with a subdistribution hazard ratio of 2.67, although the confidence interval crossed unity and the finding did not reach statistical significance. Even without formal significance, prolonged fungemia fits the biology of sustained hematogenous seeding. The longer viable organisms circulate, the more time they have to establish secondary foci.
Metastatic infection was not just a microbiologic complication. It tracked with worse survival. In time-dependent analyses, metastatic disease was associated with increased deaths at 60 days and 90 days, with adjusted hazard ratios of 2.21 and 2.26, respectively. The signal persisted after accounting for age and Charlson Comorbidity Index score, tying dissemination to downstream clinical harm rather than simple baseline frailty.
Diagnostic Yield Improved When Imaging and Microbiology Were Pursued Together
The diagnostic approach in the cohort showed how metastatic candidiasis is often confirmed in practice. Among the 24 patients with disseminated infection, imaging supported the diagnosis in 18, microbiologic confirmation from the metastatic site was obtained in 19, and histopathologic evidence was present in 4. These methods overlapped, which is typical in invasive fungal disease where tissue, imaging, and blood culture data rarely tell the full story in isolation.
Echocardiography was performed more often in patients with metastatic infection than in those without it. That difference almost certainly affected detection of endocarditis and other intracardiac complications. Fundoscopic examination did not differ significantly between groups, leaving open the possibility that ocular disease could still be underdetected in some patients, particularly if the exam is not systematically pursued.
The cohort’s treatment data did not reveal a simple explanation for who developed dissemination and who did not. Early central venous catheter removal, antifungal initiation within 48 hours, and source control within 48 hours were not significantly different between groups. Initial therapy was predominantly echinocandin-based, with amphotericin B used less often and combination therapy administered in a minority of cases. Those patterns matter because they suggest that metastatic infection was not simply the result of delayed recognition or obviously inferior initial management in the patients who later declared more extensive disease.
Endocarditis Drove the Case for Routine Cardiac Imaging in Selected Patients
The most practical message from these data centers on echocardiography. Cardiac devices and prosthetic valves identified a subgroup at particular risk for metastatic spread, and endocarditis was the leading metastatic manifestation. In a patient with C. auris candidemia and intracardiac hardware, the threshold for echocardiographic evaluation should be low. The organism’s ability to persist on prosthetic surfaces means that bloodstream clearance alone may not equal cure, especially when symptoms are muted and the infected site is hidden behind implanted material.
This is the kind of infection that can look controlled until it is not. A blood culture may clear while a valvular vegetation, device infection, or another deep focus continues to smolder.
The study also reinforces an older lesson about invasive candidiasis: the bloodstream isolate is only the opening clue. Metastatic complications may emerge after an initial episode that appears uncomplicated, particularly when candidemia lasts more than a few days or when foreign cardiac material is present.
What the Cohort Can and Cannot Prove
The data come from a single tertiary hospital in Valencia where C. auris became endemic after an outbreak in 2016. That setting strengthens internal consistency but limits how broadly the findings can be generalized. The retrospective design also leaves room for detection bias, especially because echocardiography was not uniform across all patients and the apparent risk associated with device status weakened in the echocardiography-restricted analysis.
Even so, the central clinical pattern is difficult to dismiss. In this cohort, metastatic infection affected more than one in five patients with C. auris candidemia, cardiac devices and prosthetic valves stood out as the clearest risk marker, and disseminated disease tracked with higher mortality at both 60 and 90 days. For clinicians managing this yeast, the safest assumption is that persistent candidemia and intracardiac hardware warrant a search for hidden disease rather than reassurance from the bloodstream data alone.